A carregar...
EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING
BACKGROUND: Isocitrate dehydrogenase (IDH) mutant tumors represent a distinct subtype among diffuse gliomas, with improved prognosis compared to grade-matched IDH wild-type tumors. As a basis for clinical trial design of IDH-targeting drugs, we sought to describe outcomes exclusively within the glio...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216783/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.338 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|